Predictors of mortality in individuals with disseminated histoplasmosis and advanced HIV disease
Medical Mycology · 01.05.2026 · 64 (5)
DOI: 10.1093/mmy/myag040 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Medical Mycology, online erschienen am 23.04.2026. Verfasst von Jussemara Souza da Silva und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Instituto de Infectologia Emílio Ribas, São Paulo, Brazil. Hauptthemen laut MEDLINE: Histoplasmosis, HIV Infections. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Disseminated histoplasmosis remains a major cause of morbidity and mortality among people living with advanced HIV disease (AHD), particularly in Latin America, where delayed diagnosis and limited access to optimal antifungal therapy persist. Accurate tools to assess disease severity and predict mortality are essential to guide clinical decision-making, including hospitalization, intensive care unit admission, and treatment strategies. We conducted a retrospective observational cohort study of hospitalized adults with AHD (CD4 ≤ 200 cells/mm³) and a first episode of probable or proven disseminated histoplasmosis at a tertiary referral center in São Paulo, Brazil, between 2013 and 2023. Disease severity at admission was assessed using four tools: the World Health Organization (WHO) severity classification, the Histoplasmosis Fatality Score (HFS), the Sequential Organ Failure Assessment (SOFA), and the quick SOFA (qSOFA). The primary outcome was in-hospital mortality. Eighty-nine individuals were included; most were male (77.5%), with a median age of 39 years and profound immunosuppression (median CD4 count 24 cells/mm³). In-hospital mortality was 34.8%. Individuals who died had significantly higher HFS and SOFA scores. In multivariable analysis, HFS, SOFA score, and serum creatinine were independently associated with in-hospital mortality, whereas qSOFA was not. HFS showed the best discriminatory performance (AUC 0.798; 95% CI 0.707–0.889). The combination of HFS and elevated creatinine further improved discrimination (AUC 0.840; 95% CI 0.758–0.922), outperforming the WHO classification, SOFA, and qSOFA in predicting in-hospital mortality. These findings support the use of HFS as a practical and reliable tool for stratifying disease severity, optimizing resource allocation, and guiding clinical decision-making in high-burden settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Instituto de Infectologia Emílio Ribas, São Paulo, Brazil.
- Department of Clinical Medicine and Post-Graduation Program in Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.
- Infectious Diseases Service, Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil.
- Division of Infectious Diseases, University of Minnesota, MN, USA.
- Serviço de Extensão ao Atendimento de Paciente HIV/Aids, Hospital das Clínicas, Departamento de Infectologia e Medicina Tropical, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
ORCID-Profile: Jussemara Souza da Silva, José E Vidal
Zitieren
APA
da Silva, J. S., Nuñez, V. G., de Oliveira, V. S. D., Pasqualotto, A. C., & Vidal, J. E. (2026). Predictors of mortality in individuals with disseminated histoplasmosis and advanced HIV disease. Medical Mycology, 64(5). https://doi.org/10.1093/mmy/myag040
Vancouver
da Silva JS, Nuñez VG, de Oliveira VSD, Pasqualotto AC, Vidal JE. Predictors of mortality in individuals with disseminated histoplasmosis and advanced HIV disease. Medical Mycology. 2026;64(5). doi:10.1093/mmy/myag040
BibTeX
@article{daSilva2026,
author = {da Silva, Jussemara Souza and Nuñez, Victor Garcia and de Oliveira, Victória Spínola D and Pasqualotto, Alessandro C and Vidal, José E},
title = {Predictors of mortality in individuals with disseminated histoplasmosis and advanced HIV disease},
journal = {Medical Mycology},
year = {2026},
volume = {64},
number = {5},
doi = {10.1093/mmy/myag040}
}
EUVIMED